Kestra Advisory Services, LLC Alaunos Therapeutics, Inc. Transaction History

Kestra Advisory Services, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 01, 2022	SELL	$1.04 - $322.5 $6,552 - $2.03 Million	-6,300 Reduced 32.91%	12,843 $22 Million
Q2 2022 Aug 12, 2022	BUY	$0.41 - $1.24 $2,870 - $8,680	7,000 Added 57.65%	19,143 $24,000
Q4 2021 Jan 20, 2022	SELL	$1.09 - $1.89 $545 - $945	-500 Reduced 3.95%	12,143 $13,000
Q3 2021 Oct 19, 2021	BUY	$1.44 - $2.73 $720 - $1,365	500 Added 4.12%	12,643 $23,000
Q1 2021 May 10, 2021	SELL	$2.82 - $5.6 $3,948 - $7,839	-1,400 Reduced 10.34%	12,143 $43,000
Q4 2020 Jan 20, 2021	BUY	$2.09 - $3.09 $2,299 - $3,399	1,100 Added 8.84%	13,543 $36 Million
Q3 2020 Nov 12, 2020	BUY	$2.39 - $3.43 $29,738 - $42,679	12,443 New	12,443 $31 Million

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $389M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Kestra Advisory Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Kestra Advisory Services, LLC with notifications on news.